CSL Ltd Annual Report 2021

The Patient Focus Peer Network includes key patient focus stakeholders from departments across the organisation. Members will leverage their combined experiences and serve as a guiding forum for CSL teams seeking advice and strategic input about patient-focused activities. The Patient Focus Knowledge Centre is an online, internal portal for patient engagement offering guidance and access to case studies, patient-focused resources, useful links, downloads and success stories. The CARE Network , an internal, social media platform, provides CSL employees a forum to discuss patient focus concepts and ideas. Colleagues can connect across the globe, suggest subjects for discussion and participate in innovation sessions with the aim of fostering cultural connections across CSL through meaningful conversations about work and experiences with, and for, patients. You can read more about our direct support for patient communities in Section 11 of this report. Improving patient experiences and public health This year, CSL Behring has transformed how we approach customer engagement with the implementation of a best-in-industry customer relationship management platform that empowers our people to collaborate, while providing a superior customer experience and value for patients. This new capability enables us to connect with our customers both virtually and in person. It supports our customer- facing team in providing key product information, facilitating remote education and engagement, as well as delivering newmedical insights for supporting patient care and enhancing the customer experience. As part of the CSL strategy to drive digital transformation, we aspire to support patients with information, tools and assistance to manage the treatment of their disease. In September 2020, we launched our first digital health application – MyHizentra ® for US users – on a new scalable and secure digital health platform. The MyHizentra ® application allows patients to manage their disease by scheduling and recording infusions, confidentially sharing infusion information with their doctor and accessing online support materials. With the challenges brought on by the pandemic, providing patients with the confidence and assistance they need to safely infuse at home remains of utmost importance – something we believe MyHizentra ® delivers. We seek to expand this offering into new geographies and to continue to enhance patient and caregiver experiences with CSL Behring therapies. Responsible marketing and promotion CSL recognises that reputation in the marketplace and success as a reliable supplier of biopharmaceuticals relies on ensuring our medicines are honestly represented in our interactions with healthcare professionals, consumers and other customers. Promotional Review Committees, comprising cross-functional members, operate across CSL business units to ensure compliance with all applicable local laws, regulations and accepted industry codes, such as Medicines Australia Code of Conduct (MA Code) and the European Federation of Pharmaceutical Industries and Associations Code for European Union member countries. The committees are responsible for ensuring information on medicines, vaccines and therapy areas is balanced, supported by scientifically valid data and compliant with relevant laws and codes. During 2020/21, neither CSL Behring Australia nor Seqirus Australia were found to be in breach of the MA Code. For international operations, CSL (including CSL Behring and Seqirus) was not found to be in breach of any regulation of the US FDA or the European Medicines Agency (EMA) with respect to the promotion or marketing of medicines, vaccines and therapies. 0 breaches of product marketing and promotional activities by the US FDA, EMA or Medicines Australia* Privacy and cybersecurity As automation, digital transformation and emerging technologies rapidly reshape our industry, the ecosystem of cyber risk expands exponentially, and the frequency and sophistication of cyberattacks increase. That is why CSL is committed to continually evolving our information security capabilities and strengthening protections around our most important information assets and critical infrastructure. The threats we face today can alter the landscape of our success in the future. As a result, proactively managing risk is essential to ensuring that we can deliver on our 2030 strategy and is an ongoing focus of CSL’s senior leadership group and CSL’s Audit and Risk Management Committee of the Board. Today, by taking a collaborative, enterprise-wide approach to confronting cybersecurity and privacy challenges, we are better able to meet the needs of the business. We have placed business enablement and patient and donor safety at the forefront of our cyber strategy, driving CSL to adopt innovative approaches and technologies that will enable continuous monitoring and assessment of cybersecurity threats, and prevent disruption to our supply chain, drug development and manufacturing operations. 9 A TrustedHealth Partner * Limited assurance by Ernst & Young. CSL Limited Annual Report 2020/21 48